Chronic Pain and Mental Health Comorbidity: Depression, Anxiety, Pain Catastrophizing, and Integrated Treatment Models

Chronic pain — defined as pain persisting or recurring for more than three months (ICD-11 MG30) — affects an estimated 20–30% of the global adult population, with approximately 50 million adults in the United States experiencing high-impact chronic pain that substantially restricts daily activities. What elevates chronic pain from a challenging medical condition to a psychiatric concern is the extraordinary degree to which it co-occurs with depressive disorders, anxiety disorders, and maladaptive cognitive-affective processes such as pain catastrophizing. This comorbidity is not coincidental: it reflects deeply shared neurobiological substrates, mutual amplification loops, and a fundamental overlap in how the brain processes physical suffering and emotional distress.

The clinical stakes of this comorbidity are significant. Patients with co-occurring chronic pain and depression experience greater disability, consume more healthcare resources, respond less robustly to treatment targeting either condition alone, and have markedly poorer long-term outcomes than patients with either condition in isolation. The presence of anxiety disorders and elevated catastrophizing further compounds these effects. Despite this, chronic pain and mental health conditions are frequently treated in separate clinical silos — pain clinics that undertreat psychiatric symptoms, and psychiatric settings that inadequately address pain. This article examines the bidirectional epidemiology, shared neurobiological mechanisms, clinical presentation complexities, and the evidence base for integrated treatment models that address both domains simultaneously.

The epidemiological relationship between chronic pain and psychiatric disorders is robustly bidirectional, meaning each condition substantially increases the risk of the other, though the magnitude of association varies by direction and specific disorder.

Chronic Pain → Depression

Among individuals with chronic pain conditions, the prevalence of major depressive disorder (MDD) ranges from 30% to 60%, depending on the population studied, pain condition type, and assessment methodology. A 2020 meta-analysis by IsHak and colleagues reported a pooled prevalence of clinically significant depressive symptoms in approximately 52% of chronic pain patients in specialty settings. This contrasts starkly with the 7–8% point prevalence of MDD in the general population. Specific chronic pain conditions show varying rates: fibromyalgia patients demonstrate depression rates of 40–70%, chronic low back pain 40–55%, and neuropathic pain conditions approximately 30–50%.

Depression → Chronic Pain

Conversely, among individuals presenting with MDD, the prevalence of clinically significant chronic pain symptoms ranges from 50% to 65%. The World Mental Health Survey, spanning 17 countries, found that individuals with depression were 3–4 times more likely to develop chronic pain conditions than non-depressed individuals. Notably, somatic pain complaints (headache, back pain, diffuse musculoskeletal pain) are among the most common presenting symptoms of depression in primary care, particularly in non-Western cultural contexts where somatic idioms of distress predominate.

Chronic Pain → Anxiety Disorders

Anxiety disorders co-occur with chronic pain at rates of 20% to 45%, with generalized anxiety disorder (GAD) and panic disorder being the most frequently comorbid. A systematic review by Asmundson and Katz (2009) found that anxiety disorders were present in approximately 35% of chronic pain patients, with fear-avoidance beliefs serving as a key mediating variable. Post-traumatic stress disorder (PTSD) shows a particularly strong association with chronic pain, with co-occurrence rates of 20–35% in chronic pain samples and up to 80% in certain trauma-exposed pain populations (e.g., combat veterans, motor vehicle accident survivors).

Anxiety Disorders → Chronic Pain

Among individuals with primary anxiety disorders, chronic pain prevalence is approximately 45–60%. GAD shows the strongest bidirectional association, likely because the chronic hyperarousal, muscle tension, and somatic hypervigilance characteristic of GAD directly generate nociceptive input. Panic disorder patients frequently develop chronic chest pain and headache syndromes, complicating both cardiac and neurological diagnostic workups.

Pain Catastrophizing as a Transdiagnostic Bridge

Pain catastrophizing — defined as an exaggerated negative cognitive-affective orientation toward actual or anticipated pain, encompassing rumination, magnification, and helplessness — is not a psychiatric diagnosis per se but functions as a powerful mediator of the pain-mental health relationship. Catastrophizing, as measured by the Pain Catastrophizing Scale (PCS), is elevated in 40–50% of chronic pain patients and accounts for 7–31% of variance in pain outcomes across studies, often exceeding the explanatory power of pain intensity itself.

The comorbidity between chronic pain and psychiatric disorders is not merely correlational — it reflects shared neurobiological architecture. Several converging lines of evidence explain why the brain does not cleanly separate physical pain from emotional suffering.

Overlapping Neural Circuits

Functional neuroimaging studies have consistently demonstrated that chronic pain and depression recruit overlapping cortical and subcortical networks. The anterior cingulate cortex (ACC), particularly its dorsal subdivision (dACC), is activated by both physical pain and social/emotional pain (as demonstrated in Eisenberger's landmark social exclusion studies). The insular cortex processes both interoceptive pain signals and affective states, serving as a convergence zone for nociception and emotional awareness. The prefrontal cortex (PFC), specifically the dorsolateral (dlPFC) and ventromedial (vmPFC) regions, modulates both pain perception and mood regulation — and shows reduced gray matter volume and diminished functional connectivity in both chronic pain and MDD.

The periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) form the descending pain modulatory system, which can either inhibit or facilitate nociceptive transmission at the spinal level. Depression and anxiety are associated with impairment of descending inhibitory function, effectively reducing the brain's capacity to "turn down" pain signals. This provides a concrete neuroanatomical explanation for why depressed patients experience greater pain intensity for equivalent nociceptive input.

Serotonin, Norepinephrine, and Dual-Function Neurotransmission

The monoamine neurotransmitters serotonin (5-HT) and norepinephrine (NE) are critically involved in both mood regulation and descending pain inhibition. Serotonergic projections from the dorsal raphe nucleus and noradrenergic projections from the locus coeruleus modulate spinal dorsal horn nociceptive processing. Deficiency in these systems simultaneously impairs mood regulation and weakens endogenous analgesia. This shared neurotransmitter substrate is the pharmacological rationale for the efficacy of serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine in treating both depression and chronic pain conditions — they restore function in the same descending modulatory pathways.

HPA Axis Dysregulation and Neuroinflammation

Chronic pain and depression both involve dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, with elevated cortisol, disrupted diurnal cortisol rhythms, and impaired glucocorticoid receptor sensitivity. Sustained HPA axis activation promotes a neuroinflammatory state characterized by elevated pro-inflammatory cytokines (interleukin-6, interleukin-1β, tumor necrosis factor-α). These cytokines cross the blood-brain barrier, activate microglia, reduce monoamine synthesis, and promote central sensitization — a process by which spinal and supraspinal nociceptive neurons become hyperexcitable, amplifying pain signals. Central sensitization may thus represent a shared pathophysiological endpoint for both chronic pain and depression.

Endogenous Opioid System Dysfunction

The endogenous opioid system (β-endorphin, enkephalins, dynorphins acting at μ, δ, and κ receptors) modulates both pain and reward/pleasure circuits. Chronic pain is associated with downregulation of μ-opioid receptor availability in the ACC and thalamus, while depression involves reduced opioidergic tone in reward circuits. The shared depletion of endogenous opioid resources may contribute to the simultaneous experience of increased pain sensitivity and anhedonia.

Neuroplastic Changes

Both chronic pain and depression are characterized by maladaptive neuroplastic changes, including hippocampal volume reduction, reduced brain-derived neurotrophic factor (BDNF) levels, and altered default mode network (DMN) connectivity. The DMN, involved in self-referential processing and rumination, shows increased connectivity in both chronic pain and depression — consistent with the cognitive ruminative processes central to pain catastrophizing and depressive rumination.

The co-occurrence of chronic pain and psychiatric disorders does not simply add symptom burdens — it fundamentally alters clinical presentation in ways that challenge diagnostic accuracy and treatment planning.

Somatic Masking of Depression

In primary care settings, up to 69% of patients with MDD present with somatic pain complaints as their chief concern rather than reporting depressed mood or anhedonia (Simon et al., 1999). Low back pain, headache, diffuse myalgia, and abdominal pain are among the most common presenting symptoms. Clinicians who pursue exclusively biomedical pain workups without screening for depression may miss the psychiatric diagnosis entirely, leading to unnecessary imaging, procedures, and opioid prescriptions while the underlying depression goes untreated.

Pain Amplification in Depression

Depression lowers pain thresholds and pain tolerance through the neurobiological mechanisms described above. Patients with comorbid depression report higher pain intensity ratings, greater functional impairment, and more widespread pain distribution than pain-matched controls without depression. This can lead to diagnostic confusion: clinicians may suspect pain exaggeration or malingering when in fact the patient's subjective pain experience is genuinely amplified by depressive neurobiology.

Anxiety-Driven Hypervigilance and Avoidance

Comorbid anxiety disorders promote somatic hypervigilance — an attentional bias toward body sensations that amplifies the perceived severity of nociceptive signals. This drives the fear-avoidance model described by Vlaeyen and Linton (2000), in which pain-related fear leads to behavioral avoidance of movement, progressive deconditioning, increased disability, and paradoxically greater pain through disuse and central sensitization. The resulting clinical picture can mimic severe structural pathology despite modest objective findings.

Clinical Vignette: Diagnostic Complexity in Practice

A 42-year-old woman presents to her primary care physician with a 14-month history of worsening low back pain, fatigue, poor sleep, and difficulty concentrating at work. She has been evaluated by two orthopedists; MRI reveals only mild degenerative disc changes typical for her age. She has tried physical therapy with minimal improvement. On closer questioning, she reports losing interest in hobbies, social withdrawal, and persistent feelings of worthlessness. She scores 18 on the PHQ-9 (moderately severe depression) and 28 on the Pain Catastrophizing Scale (clinically elevated). She denies feeling "depressed" but acknowledges that "the pain has taken everything from me." Her previous providers attributed all symptoms to her back pain and prescribed escalating doses of opioids, which provided minimal relief and may have worsened her mood. This presentation illustrates how depression can be concealed behind chronic pain, how catastrophizing magnifies disability disproportionate to pathology, and how treatment that targets pain alone without addressing the psychiatric comorbidity is likely to fail.

Clinical Vignette: PTSD and Chronic Pain

A 34-year-old male veteran presents to a pain clinic with severe bilateral knee pain, chronic headaches, and diffuse muscle tension following a deployment-related blast injury two years prior. He reports nightmares, hyperstartle, irritability, and avoidance of crowded places. He minimizes psychological symptoms, stating "I just need something for the pain." His pain intensity ratings fluctuate dramatically — baseline VAS 4/10 that spikes to 9/10 during periods of increased PTSD symptom severity. His pain is refractory to NSAIDs, gabapentin, and physical therapy. His treating providers have not connected his pain exacerbations to PTSD flares. This case demonstrates the intimate temporal relationship between PTSD symptoms and pain amplification, the tendency for patients to present somatic rather than psychological complaints, and the futility of addressing pain independently of the co-occurring psychiatric disorder.

Comorbid mental health conditions profoundly influence treatment outcomes for chronic pain, and vice versa. Ignoring this bidirectional impact leads to treatment resistance, polypharmacy, and patient frustration.

Depression Worsens Pain Treatment Outcomes

A consistent finding across pain treatment modalities is that comorbid depression predicts poorer outcomes. In the context of spinal surgery, patients with untreated depression have significantly lower rates of functional improvement and higher rates of persistent post-surgical pain. A prospective study by Sinikallio et al. (2011) found that preoperative depression was the strongest psychological predictor of dissatisfaction and ongoing disability after lumbar spine surgery. Similarly, comorbid depression reduces adherence to physical therapy and exercise-based rehabilitation — the cornerstone of chronic pain management — by diminishing motivation, energy, and self-efficacy.

Chronic Pain Reduces Antidepressant Response

Data from the STAR*D trial revealed that depressed patients with comorbid pain had lower remission rates to antidepressant treatment than depressed patients without pain. Pain was associated with approximately 10–15% lower remission rates across sequential treatment steps. This finding has been replicated in multiple naturalistic studies and underscores that achieving depression remission is substantially more difficult when chronic pain is present.

Catastrophizing as a Treatment Moderator

Elevated pain catastrophizing predicts poor outcomes across nearly all chronic pain treatments, including medications, physical therapy, injections, and surgery. In a landmark study, Wertli et al. (2014) conducted a systematic review showing that high baseline catastrophizing was associated with poorer outcomes across diverse interventions, while reductions in catastrophizing during treatment mediated improvements in pain and disability. This has led to growing consensus that catastrophizing should be a specific treatment target rather than merely a prognostic marker.

Pharmacological Considerations

The pharmacological overlap between pain and depression treatment offers both opportunities and pitfalls:

• SNRIs (duloxetine, venlafaxine, milnacipran): Duloxetine has the strongest evidence base for dual efficacy. In chronic musculoskeletal pain, duloxetine 60–120 mg/day produces a number needed to treat (NNT) of approximately 5–8 for ≥30% pain reduction and has well-established antidepressant efficacy. It is FDA-approved for MDD, GAD, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain.
• Tricyclic antidepressants (amitriptyline, nortriptyline): These agents have an NNT of approximately 3–4 for neuropathic pain (Finnerup et al., 2015 meta-analysis) and carry antidepressant properties, though anticholinergic side effects limit tolerability. They remain first-line for neuropathic pain conditions.
• SSRIs: Selective serotonin reuptake inhibitors are effective antidepressants but have weaker analgesic properties than dual-reuptake agents. They may be appropriate when depression is the predominant concern and pain is mild, but they are not recommended as primary analgesics.
• Gabapentinoids (pregabalin, gabapentin): These agents have evidence for neuropathic pain and fibromyalgia (pregabalin NNT approximately 7–8 for fibromyalgia) and show anxiolytic properties, particularly pregabalin (which is approved for GAD in Europe). They do not, however, have meaningful antidepressant effects.
• Opioids: Long-term opioid therapy for chronic non-cancer pain is increasingly discouraged due to limited efficacy evidence beyond 12 weeks, risk of opioid use disorder, and potential to worsen depression through opioid-induced hyperalgesia, hormonal disruption, and reward circuit downregulation. In patients with comorbid depression, opioid prescribing carries additional risk of intentional overdose.

Given the deeply entwined nature of chronic pain and mental health conditions, the question of how to structure treatment — integrated (simultaneous) versus sequential (one condition first, then the other) — carries significant clinical implications.

The Case for Integrated Treatment

Integrated treatment addresses chronic pain and psychiatric comorbidity concurrently within a coordinated framework. The evidence strongly favors this approach over sequential or fragmented care:

The IMPACT (Improving Mood—Promoting Access to Collaborative Treatment) trial demonstrated that a collaborative care model for depression in older adults with comorbid pain led to significant improvements in both depressive symptoms and pain intensity, disability, and health-related quality of life. Patients in the collaborative care arm were twice as likely to achieve 50% improvement in depressive symptoms compared to usual care, with concurrent reductions in pain interference.

The STEP-BD and related stepped-care models in pain populations have shown that integrating behavioral health into pain management produces effect sizes for pain reduction (Cohen's d = 0.3–0.6) and depression improvement (d = 0.4–0.8) that exceed what is achieved when either domain is treated independently.

Cognitive Behavioral Therapy: The Strongest Psychotherapy Evidence

Cognitive behavioral therapy (CBT) for chronic pain has the largest evidence base of any psychological intervention. A Cochrane review by Williams, Eccleston, and Morley (2012, updated 2020) reported small to moderate effect sizes for CBT on pain (SMD = −0.21), disability (SMD = −0.26), and mood (SMD = −0.38) at post-treatment, with effects maintained at follow-up. When CBT specifically targets pain catastrophizing and comorbid depression simultaneously, effect sizes for both outcomes are larger than when either is targeted alone.

Key CBT components in integrated pain-mental health treatment include:

• Cognitive restructuring of pain catastrophizing beliefs ("This pain means I am being damaged" → "Pain is not always a sign of harm")
• Behavioral activation to counter both depressive withdrawal and fear-avoidance
• Graded exposure to feared movements and activities
• Sleep hygiene interventions (insomnia is comorbid in 50–75% of chronic pain patients and independently worsens both pain and depression)
• Relaxation training and stress management to reduce autonomic arousal

Acceptance and Commitment Therapy (ACT)

ACT has emerged as a strong alternative or complement to traditional CBT for chronic pain. ACT targets psychological flexibility — the ability to engage in valued activities despite pain and distress — rather than directly attempting to reduce pain or change pain cognitions. A meta-analysis by Hughes et al. (2017) reported moderate effect sizes for ACT on pain interference (g = 0.57), depression (g = 0.37), and anxiety (g = 0.33) in chronic pain populations. ACT may be particularly well-suited for patients with long-duration chronic pain where pain reduction is unlikely, as it decouples functioning from pain intensity.

Interdisciplinary Pain Rehabilitation Programs (IPRPs)

IPRPs represent the gold standard of integrated treatment, typically involving coordinated input from pain medicine physicians, psychologists, physical therapists, occupational therapists, and sometimes psychiatrists and social workers. A systematic review by Kamper et al. (2015) found that multidisciplinary rehabilitation for chronic low back pain produced meaningful improvements in pain (SMD = −0.55) and function (SMD = −0.41) compared to physical treatments alone, with effects maintained at 12 months. Importantly, IPRPs explicitly address the psychological dimensions of chronic pain, including depression, anxiety, catastrophizing, and fear-avoidance.

Despite their efficacy, IPRPs face significant access barriers: they are resource-intensive, geographically concentrated, and often inadequately covered by insurance. This has spurred interest in digital and telehealth-delivered integrated interventions.

Sequential Treatment: When It May Be Appropriate

Sequential treatment may be warranted when one condition is clearly primary and severely destabilizing. For example, a patient with severe suicidal depression and moderate chronic pain may require stabilization of the psychiatric crisis before engaging in active pain rehabilitation. Similarly, acute pain exacerbations requiring urgent medical management may temporarily take precedence over psychological treatment. However, the evidence suggests that prolonged sequential approaches — treating pain "first" with the assumption that mood will improve secondarily, or vice versa — are generally inferior to concurrent strategies.

The presence of psychiatric comorbidity in chronic pain carries substantial prognostic significance across multiple outcome domains.

Disability and Functional Impairment

Comorbid depression approximately doubles the odds of disability in chronic pain populations. The WHO World Mental Health Survey found that the combination of chronic pain and depression produced disability scores that exceeded the additive effect of either condition alone — suggesting a synergistic rather than merely additive interaction. Patients with comorbid chronic pain and PTSD show even greater functional impairment, particularly in occupational and social domains.

Chronicity and Treatment Resistance

Untreated psychiatric comorbidity is one of the strongest predictors of pain chronification — the transition from acute or subacute pain to chronic pain. The fear-avoidance model posits that psychological factors (catastrophizing, depression, anxiety) are more important than biomedical factors in determining whether an acute pain episode resolves or becomes persistent. Prospective studies of acute low back pain consistently show that psychological variables at baseline (especially catastrophizing and depressive symptoms) predict chronic pain development more strongly than initial pain intensity or radiographic findings.

Suicidality

The combination of chronic pain and depression carries substantially elevated suicide risk. A meta-analysis by Racine (2018) found that chronic pain was associated with approximately twice the odds of suicidal ideation and suicide attempts. When depression is comorbid, this risk is further compounded. Clinicians treating chronic pain patients should routinely assess for suicidal ideation, particularly when depression is present, pain is poorly controlled, or functional capacity is declining.

Healthcare Utilization and Costs

Patients with comorbid chronic pain and depression incur healthcare costs that are 2–5 times higher than patients with either condition alone, driven by emergency department visits, hospitalizations, polypharmacy, and repeated specialist consultations. Integrated treatment models have demonstrated cost-effectiveness by reducing fragmented utilization and improving outcomes simultaneously.

Given the high bidirectional prevalence and significant prognostic implications, systematic screening for psychiatric comorbidity in chronic pain patients — and for chronic pain in psychiatric patients — should be considered standard practice.

Screening for Depression and Anxiety in Chronic Pain Settings

• PHQ-9 (Patient Health Questionnaire-9): A well-validated, brief self-report measure for depressive symptom severity. A score ≥10 suggests moderate depression warranting further evaluation. Sensitivity of approximately 88% and specificity of approximately 85% for MDD in chronic pain populations.
• GAD-7 (Generalized Anxiety Disorder 7-item scale): Screens for GAD and general anxiety severity. A score ≥10 indicates moderate anxiety. Performs well in chronic pain samples.
• PC-PTSD-5: A 5-item primary care screen for PTSD, particularly relevant in pain populations with trauma exposure. A score ≥3 warrants full PTSD assessment.

Screening for Pain Catastrophizing

• Pain Catastrophizing Scale (PCS): A 13-item measure with subscales for rumination, magnification, and helplessness. A total score ≥30 is considered clinically significant and identifies patients at high risk for poor outcomes.
• Tampa Scale of Kinesiophobia (TSK): Assesses fear of movement and reinjury, a key component of the fear-avoidance model. Elevated scores (≥37) predict avoidance behavior and poor rehabilitation participation.

Screening for Pain in Psychiatric Settings

• Brief Pain Inventory (BPI): Assesses both pain intensity and pain interference across functional domains. Should be routinely administered to patients presenting with depression, anxiety, or PTSD, as pain complaints may not be spontaneously reported.
• Simple visual analog scales (VAS) or numeric rating scales (NRS 0–10) can serve as initial screens, but dimensional assessment of pain interference is more clinically informative than intensity alone.

Recommended Screening Protocol

Current best practice, supported by VA/DoD clinical guidelines and the International Association for the Study of Pain (IASP), recommends:

• Universal depression and anxiety screening at intake for all chronic pain patients, repeated at regular intervals (e.g., every 3–6 months)
• Pain catastrophizing assessment at baseline and as a treatment process measure
• Routine pain screening in all patients presenting with new or treatment-resistant depression
• Suicide risk assessment in all patients with comorbid chronic pain and depression

Despite substantial progress in understanding the pain-mental health intersection, significant research gaps remain, alongside promising emerging directions.

Neuroimaging Biomarkers

Emerging research aims to identify neuroimaging signatures that predict which pain patients will develop depression, or which depressed patients will develop chronic pain. Studies using machine learning applied to resting-state fMRI data have identified connectivity patterns in the medial prefrontal cortex, nucleus accumbens, and amygdala that predict pain chronification with moderate accuracy (70–80% classification accuracy in preliminary studies). These approaches remain experimental but could eventually enable early identification and preventive intervention.

Ketamine and Psychedelics

Ketamine, an NMDA receptor antagonist with rapid antidepressant properties, is being studied as a dual-target agent for comorbid chronic pain and depression. Preliminary evidence suggests that subanesthetic ketamine infusions produce concurrent improvements in both depression and certain chronic pain conditions (particularly neuropathic pain and complex regional pain syndrome), though the durability of effects remains unclear. Psilocybin-assisted therapy for treatment-resistant depression is also being explored in chronic pain populations, with early-phase studies investigating whether psychedelic-facilitated changes in self-referential processing and catastrophizing can produce lasting pain-related benefits.

Digital Therapeutics and Telehealth

The accessibility gap for integrated pain-mental health treatment has spurred development of digital CBT and ACT programs. Programs such as Curable, FIT-HIP, and Internet-delivered CBT for chronic pain have shown small to moderate effect sizes in randomized controlled trials, with the advantage of scalability. Telehealth-delivered interdisciplinary pain programs, expanded rapidly during the COVID-19 pandemic, have demonstrated non-inferiority to in-person programs in initial studies.

Gut-Brain Axis

Emerging research on the microbiome-gut-brain axis suggests that gut dysbiosis may contribute to both chronic widespread pain (particularly fibromyalgia and irritable bowel syndrome) and depression via systemic inflammation, altered tryptophan metabolism, and vagal nerve signaling. This represents a potential novel therapeutic target, though evidence is currently at the pre-clinical and early correlational stage.

Key Research Gaps

• Mechanism-based treatment matching: Which patients with comorbid pain and depression respond best to pharmacological vs. psychological vs. combined approaches? Current evidence does not support reliable personalization.
• Long-term outcomes: Most integrated treatment trials report 6–12 month follow-up at most. The durability of integrated treatment effects beyond one year is poorly characterized.
• Pediatric and geriatric populations: The chronic pain-mental health intersection is understudied in children/adolescents and older adults, who have distinct neurobiological vulnerabilities and treatment considerations.
• Racial and ethnic disparities: Pain assessment and psychiatric comorbidity detection are affected by clinician bias, cultural presentation differences, and systemic healthcare inequities. Research on how these disparities manifest in comorbid pain-mental health treatment is limited.
• Prevention: Whether early psychological intervention during acute pain episodes can prevent both pain chronification and the development of psychiatric comorbidity is a critical unanswered question with enormous public health implications.

The evidence reviewed in this article supports several actionable clinical principles for providers working at the intersection of chronic pain and mental health:

• Screen routinely and bidirectionally. Every chronic pain patient should be assessed for depression, anxiety, PTSD, and pain catastrophizing. Every patient with a depressive or anxiety disorder should be asked about pain. Validated brief measures exist for all of these constructs.
• Treat comorbidity concurrently, not sequentially. Integrated approaches addressing pain and mental health simultaneously produce superior outcomes to treating one condition in isolation. Waiting for one condition to "resolve" before addressing the other is rarely effective, as the conditions mutually reinforce each other.
• Target catastrophizing explicitly. Pain catastrophizing is one of the most potent and modifiable predictors of chronic pain outcomes. CBT and ACT both demonstrate efficacy in reducing catastrophizing, and change in catastrophizing mediates improvements in both pain and mood.
• Select pharmacotherapy that addresses both domains when possible. SNRIs, particularly duloxetine, and TCAs for neuropathic pain conditions offer dual benefits. Avoid relying on opioids for comorbid pain and depression, as they may worsen both conditions long-term.
• Adopt interdisciplinary care models when available. The evidence base for interdisciplinary pain rehabilitation is robust, and these programs address the biopsychosocial complexity of comorbid presentations more effectively than any single-modality treatment.
• Assess suicide risk. The combination of chronic pain, depression, and hopelessness creates a particularly high-risk profile that requires proactive and repeated assessment.
• Educate patients about the pain-mood connection. Many patients resist or misunderstand the association between pain and mental health, often perceiving psychological explanations as dismissive of their pain. Providing neurobiological explanations ("Depression changes how your brain processes pain signals") can enhance treatment engagement and reduce stigma.